Octreotide Uptake in Parathyroid Adenoma

Creative Commons License

Karacavus S., Kula M., ÖZDAMAR KARACA Z. C., ÜNLÜHİZARCI K., TUTUŞ A., BAYRAM F., ...Daha Fazla

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, cilt.21, sa.2, ss.77-79, 2012 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.4274/mirt.4
  • Dergi Adı: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.77-79
  • Anahtar Kelimeler: Parathyroid adenoma, indium-111-octreotide, somatostatin
  • Erciyes Üniversitesi Adresli: Evet

Özet

The patient with a history of bone pain and muscle weakness, was thought to have oncogenic osteomalacia as a result of biochemical investigations and directed to Nuclear Medicine Department for a whole-body bone scintigraphy and In-111-octreotide scintigraphy. There was no focal pathologic tracer uptake, but generalized marked increase in skeletal uptake on bone scintigraphy. Octreotide scintigraphy showed accumulation of octreotide in the region of the left lobe of the thyroid gland in the neck. Thereafter, parathyroid scintigraphy was performed with technetium-99m labeled metroxy-isobutyl-isonitryl (Tc-99m-MIB) and MIBI scan demonstrated radiotracer uptake at the same location with octreotide scintigraphy. The patient underwent left inferior parathyroidectomy and histopathology confirmed a parathyroid adenoma. Somatostatin receptor positive parathyroid adenoma may show octreotide uptake. Octreotide scintigraphy may be promising and indicate a possibility of using somatostatin analogues for the medical treatment of somatostatin receptor positive parathyroid tumors.